Recently, many foreign-funded brokerages have expressed their views on the A** market in 2024. Goldman Sachs said it expects the MSCI China Index and CSI 300 Index to return 17% and 19% respectively in 2024, and recommends maintaining an "overweight" on China A-shares. UBS said that the worst of A-shares has passed and it has begun to shift to optimism.
On January 10, Goldman Sachs Chief China Strategist Liu Jinjin and his team released the latest view that if the earnings of listed companies can achieve about 10% growth and China's support policies are effectively implemented, the MSCI China Index and the CSI 300 Index are expected to return 17% and 19% respectively in 2024.
Liu Jinjin suggested that the "high allocation" of China A-shares should be maintained. In terms of sectors, we are bullish on TMT, hard technology, consumer staples and medical equipment sectors**.
The worst of A-shares has passed, and we are starting to shift to optimism. On January 8, Meng Lei, a strategic analyst at UBS China, said publicly.
Meng Lei**, the profit growth rate of the CSI 300A-share benchmark index in 2024 will be about 8%, higher than the growth of 2%-3% in 2023; In terms of policy, it is expected that there will be some room for RRR and interest rate cuts this year, and the policy easing will be stronger, which will have a relatively positive effect on the overall market boost.
We believe that northbound funds are now at the bottom, and there will be signs of gradual return throughout the year. Meng Lei pointed out.
In terms of investment advice, UBS pointed out that there are investment opportunities in green, healthcare, consumption, aging and intelligence. In addition, the demographics of the global market, including China, have changed, and there are many opportunities in the direction of aging, including artificial intelligence, robotics, etc.